CVS Health's poor 2024 performance could be turning around in 2025 with a new CEO and potential rebound, despite challenges.
Hosted on MSN8h
UnitedHealth's OptumRx Accused of Excessive Drug PricingThe Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...
CVS Health shares are trading lower by 2.7% during Thursday's session. Shares of insurers and pharmacy benefit manager stocks ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Shares of CVS Health Corp. CVS advanced 1.11% to $52.14 Wednesday, on what proved to be an all-around favorable trading ...
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback